TheStreet's Jim Cramer says investors need to see money come back to high-growth names, which have seen a shrinking price-to-earnings multiple. Celgene has been in a decline but the company could have $15-$16 earnings power in a couple of years, says Cramer, and it is cheaper than Merck and Pfizer. Cramer is also watching Salesforce.com, which has seen a shrinking multiple since it reported a great quarter. If Celgene and Salesforce turn around, money will come back to high-growth from value names.

At the time of publication, Cramer was long ___.

More from Video

KPMG US Chair and CEO: Survey Shows CEOs are Still Worried About Cyber

KPMG US Chair and CEO: Survey Shows CEOs are Still Worried About Cyber

Rent the Runway co-founder Chats with Cramer on Equal Pay and a Good Pair Jeans

Rent the Runway co-founder Chats with Cramer on Equal Pay and a Good Pair Jeans

Video: Jim Cramer Reacts to Tiffany's Better Than Expected Earnings

Video: Jim Cramer Reacts to Tiffany's Better Than Expected Earnings

Jim Cramer: Union Pacific Is Positive on NAFTA Talks

Jim Cramer: Union Pacific Is Positive on NAFTA Talks

Jim Cramer: I Remain Constructive on Micron Shares

Jim Cramer: I Remain Constructive on Micron Shares